Skip to content

Palliative use of nasal high-flow oxygen compared with standard therapy in do-not-intubate patients: A randomized crossover study

Palliative use of nasal high-flow oxygen compared with standard therapy in do-not-intubate patients: A randomized crossover study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20171107001
Enrollment
38
Registered
2017-11-07
Start date
2017-11-17
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dypsnea in do&#45

Interventions

92% for hypercapnic participants for 60 minutes. After that&#44
high flow oxygen is delivered by OptiflowTM cannula using an AirvoTM flow source (Fisher & Paykel Healthcare Ltd). The initial flow will be set at 35 L/min and can be increased up to 60 L/min. FiO2 wi
92% for hypercapnic participants and maintain there for 60 minutes.,High flow oxygen is delivered by OptiflowTM cannula using an AirvoTM flow source (Fisher & Paykel Healthcare Ltd). The initial flow
92% for hypercapnic participants and maintain there for 60 minutes. After that&#44
92% for hypercapnic participants for 60 minutes.
Experimental Procedure/Surgery,Experimental Procedure/Surgery
Plan A,Plan B

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age > 18 years old 2. Do&#45;not&#45;intubate status 3. Presented with respiratory distress meeting all of the following criteria a. Pulse oximetry < 90% when breathing at room air b. Dyspnea (modified Borg scale ≥ 4) c. Signs of respiratory distress e.g. accessory muscle use d. Respiratory rate ≥ 30 breaths/min 4. Competent status: Kelly score < 4

Exclusion criteria

Exclusion criteria: 1. Refusal of treatment 2. Agitation or non&#45;cooperation 3. Adverse reactions or contraindication to opioids 4. Participants contraindicated for NHF such as excessive secretion&#44; risk of aspiration

Design outcomes

Primary

MeasureTime frame
Decrease in degree of dypsnea 15th&#44; 30th&#44; 60th&#44; 75th&#44; 90th&#44; 120th minute Modified Borg scale

Secondary

MeasureTime frame
Degree of dyspnea 15th&#44; 30th&#44; 60th&#44; 75th&#44; 90th&#44; 120th minute Numeric rating scale,Total morphine use in 1&#45;hour and 2&#45; hour period milligram,Respiratory rate 15th&#44; 30th&#44; 60th&#44; 75th&#44; 90th&#44; 120th minute Direct auscultation of respiratory cycle,SpO2 15th&#44; 30th&#44; 60th&#44; 75th&#44; 90th&#44; 120th minute pulse oximetry,Heart rate and blood pressure 15th&#44; 30th&#44; 60th&#44; 75th&#44; 90th&#44; 120th minute automatic blood pressure and heart rate monitor,Adverse event rate from equipment use within 2 hour of intervention Patient reported by themself,Hospital length of stay Until hospital discharge Hours&#44; days,Mortality rate Until hospital discharge Discharge status

Countries

Thai

Contacts

Public ContactOnlak Ruangsomboon

Department of emergency medicine&#44; faculty of medicine siriraj hospital&#44; mahidol university

foxyladymo@gmail.com+668 77853385

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026